Avapritinib - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for avapritinib and what is the scope of patent protection?
Avapritinib
is the generic ingredient in one branded drug marketed by Blueprint Medicines and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Avapritinib has forty-seven patent family members in thirty-one countries.
Summary for avapritinib
International Patents: | 47 |
US Patents: | 3 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 36 |
Clinical Trials: | 12 |
Patent Applications: | 121 |
What excipients (inactive ingredients) are in avapritinib? | avapritinib excipients list |
DailyMed Link: | avapritinib at DailyMed |
Recent Clinical Trials for avapritinib
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Theseus Pharmaceuticals | Phase 1/Phase 2 |
Blueprint Medicines Corporation | Phase 4 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for avapritinib
EU/EMA Drug Approvals for avapritinib
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines (Netherlands) B.V. | Ayvakyt | avapritinib | EMEA/H/C/005208 Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. |
Authorised | no | no | yes | 2020-09-24 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for avapritinib
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Lithuania | 3057969 | See Plans and Pricing | |
South Korea | 20160062173 | KIT에 관련된 장애를 치료하는데 유용한 조성물 (COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT) | See Plans and Pricing |
Netherlands | 301094 | See Plans and Pricing | |
South Korea | 102378689 | See Plans and Pricing | |
Norway | 2021012 | See Plans and Pricing | |
World Intellectual Property Organization (WIPO) | 2015057873 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for avapritinib
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3057969 | C20210005 00320 | Estonia | See Plans and Pricing | PRODUCT NAME: AVAPRITINIIB;REG NO/DATE: EU/1/20/1473 25.09.2020 |
3057969 | CA 2021 00008 | Denmark | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/20/1473 20200925 |
3057969 | PA2021003,C3057969 | Lithuania | See Plans and Pricing | PRODUCT NAME: AVAPRITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
3057969 | 2190008-9 | Sweden | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/20/1473 20200925 |
3057969 | LUC00199 | Luxembourg | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925 |
3057969 | 21C1013 | France | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |